Loading...
Market
What will be the outcome of BioNTech and MediLink's Phase 1 trial of BNT326/YL202 by end of 2024?
2
Resolution / Starting Odds
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Peer-reviewed journals, official announcements from BioNTech, MediLink Therapeutics, or the FDA
Story
FDA Lifts Hold on BioNTech's BNT326/YL202 Cancer Drug Trial
Aug 19, 2024, 11:40 AM
BioNTech announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on its experimental cancer drug trial. The trial involves BNT326/YL202, an anti-HER3 antibody-drug conjugate (ADC), developed in partnership with MediLink Therapeutics. The FDA's decision allows the companies to restart the phase 1 trial, with the stipulation that only lower doses will be used.
View original story
Similar markets
Trial Resumed • 33%
Trial Terminated • 33%
Trial Modified • 34%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Significant Improvement • 33%
No Change • 33%
Significant Adverse Effects • 34%
Hold Lifted • 33%
Hold Extended • 33%
New Restrictions • 34%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Significant survival improvement • 25%
Partial survival improvement • 25%
No significant change • 25%
Deterioration • 25%
Successful • 50%
Unsuccessful • 50%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%